Development of Replication-Defective HIV as Vaccine Candidate

复制缺陷型艾滋病毒候选疫苗的开发

• 批准号: 10667356
• 负责人: FRANK TUNG
• 金额: $ 30万
• 依托单位: GENECURE, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10667356
• 关键词: Antibody Response; Antigens; Development; Generations; Goals; HIV; HIV vaccine; HIV-1 vaccine; Son of Sevenless Proteins; base; design; neutralizing antibody; novel; programs; response; vaccine candidate; vaccine platform

Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines: Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broadly neutralizing antibody (bNAb) responses and novel platforms for immunogen delivery. The goal of this program is to develop an HIV vaccine platform for delivery of HIV Env immunogens that induce bnAbs and to demonstrate that the vaccine platform/immunogen proposed will elicit a strong and durable NAb HIV Env response.

用于HIV疫苗的HIV包膜免疫原的递送和/或表达的新平台：开发有效HIV疫苗的努力集中在用于诱导和产生广泛中和抗体（bNAb）应答的HIV包膜（Env）免疫原的设计的改进和用于免疫原递送的新平台。该项目的目标是开发一种HIV疫苗平台，用于递送诱导bnAb的HIV Env免疫原，并证明所提出的疫苗平台/免疫原将引起强烈和持久的NAb HIV Env应答。